We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Anbio Biotechnology Presents Point-Of-Care IVD Solutions

By LabMedica International staff writers
Posted on 08 Feb 2024

Anbio Biotechnology (Frankfurt, Germany) is demonstrating its FIA, CLIA, LAMP, and dry chemistry analyzers, along with other easy-to-use diagnostic solutions, at Medlab Middle East 2024. More...

During the trade show, Anbio is showcasing its fluorescence immunoassay (FIA) solutions which include four types of analyzers, from portable handheld to bench-top sizes, as well as a wide range of assays. 78 available assays enable the detection of a variety of analytes, including hormones, cancer markers, cardiac markers, drugs of abuse, inflammation, and infectious diseases. Also on display is Anbio’s ADL i1910 chemiluminescence immunoassay analyzer which is designed to transform the landscape of clinical diagnostics. With an impressive range of 50 CE-marked assays, this fully automated, high throughput, compact CLIA analyzer supports both qualitative and quantitative testing of analytes.

At Medlab Middle East 2024, Anbio is presenting the SHA-100 small-sized, portable, and easy-to-use dry-chemistry analyzer that supports real-time testing and real-time printing of quantitative detection results for 18 test items. Anbio is also demonstrating its LAMP Solution, a diagnostic technique to amplify and detect specific DNA or RNA sequences that is used for various applications, including detecting infectious diseases, genetic disorders, and foodborne pathogens. Anbio’s LAMP solution offers miniaturized analyzers, which are extremely easy to use. The egg-shaped LAMP device is a one-button control capable of delivering fast, sensitive, and specific results for various infectious diseases. It is suitable for over-the-counter (OTC) and point-of-care (POC) diagnostics.

For the first time, Anbio is showcasing the ABO & Rhd Blood Grouping Kit, a qualitative detection test kit for the ABO and D antigen of the Rhd blood group system on human red blood cells in whole blood or 10% red cell suspensions in physiological saline. The ABO & Rhd Blood Grouping Kit is based on the principle of antigen-antibody dot immune filtration assay to provide convenience and accuracy in testing blood types for clinical use and emergencies. It can acquire accurate results from fresh fingertip blood in as little as one minute, with a storage time of 24 months, and does not require special refrigeration or cold-chain transportation. It can quickly display blood type information through paper strip reactions, representing a modern approach to blood type testing.

"Anbio is consistently dedicated to developing easy-to-access and reliable diagnostic test kits for improving user experience in various application scenarios," said Michael Lau, CEO of Anbio Biotechnology. "Anbio's ABO & Rhd Blood Grouping Kit provides a simple way for blood type testing with low requirements for user environment, storage, and transportation while ensuring the accuracy of the results. The target market of this product will be mainly focusing on the Middle East, Asia, and Africa regions. We will continue to invest in user-centric, affordable, and reliable Point-of-Care Testing solutions and bring them to the world."

Related Links:
Anbio Biotechnology


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
MEDLAB 2024
Copyright © 2000-2026 Globetech Media. All rights reserved.